Literature DB >> 21645500

LecT-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine.

Atsushi Kuno1, Yuzuru Ikehara, Yasuhito Tanaka, Kozue Saito, Kiyoaki Ito, Chikayuki Tsuruno, Shinya Nagai, Youichi Takahama, Masashi Mizokami, Jun Hirabayashi, Hisashi Narimatsu.   

Abstract

BACKGROUND: A quantitative analysis of glyco-alteration in serum glycoproteins provides glyco-parameters for estimating the progression of liver fibrosis. In the analysis of glycans, a manual pretreatment process for clinical specimens leads to a complicated manipulation and loss-of-clinical implementation of the assay.
METHOD: We evaluated an automated triplex lectin-antibody sandwich immunoassay assisted by an automated protein purification system (ED-01) and a bedside clinical chemistry analyzer (HISCL) for the acquisition of two glyco-parameters (AOL/DSA and MAL/DSA) derived from a fibrosis-related glyco-alteration of serum alpha1-acid glycoprotein (AGP).
RESULTS: We adjusted the auto-machines with their accuracy set to CV <5.0% (ED-01) and <1.0% (HISCL). AGP samples were enriched from 275 serum specimens. Two glyco-parameters obtained by HISCL showed a linear correlation with that from a reported assay (R>0.90). The formula for monitoring fibrosis (LecT-Hepa) was given by a combination of the glyco-parameters. This correlated with the fibrosis stage from biopsy (R=0.68) and diagnosed severe fibrosis and cirrhosis. It was superior to that of FIB-4 index.
CONCLUSIONS: We automated a multilectin-assisted immunoassay with an order of magnitude reduction of operation time without any loss-of-accuracy. LecT-Hepa is a reliable method to assess fibrosis-dynamics from moderate fibrosis to cirrhosis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645500     DOI: 10.1016/j.cca.2011.05.028

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Strategy for development of clinically useful glyco-biomarkers.

Authors:  Hisashi Narimatsu
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

2.  LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients.

Authors:  Xia Zou; Xiumei Chi; Yu Pan; Dongning Du; Haibo Sun; Atsushi Matsuda; Wei Li; Atsushi Kuno; Xinxin Zhang; Hisashi Narimatsu; Junqi Niu; Yan Zhang
Journal:  Clin Proteomics       Date:  2014-12-11       Impact factor: 3.988

3.  Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.

Authors:  Hongqin Xu; Wenli Kong; Lei Liu; Xiumei Chi; Xiaomei Wang; Ruihong Wu; Xiuzhu Gao; Huan Wang; Limei Qu; Yue Qi; Yu Pan; Junqi Niu
Journal:  BMC Gastroenterol       Date:  2017-05-10       Impact factor: 3.067

4.  Qualitative and quantitative alterations in intracellular and membrane glycoproteins maintain the balance between cellular senescence and human aging.

Authors:  Yoko Itakura; Norihiko Sasaki; Masashi Toyoda
Journal:  Aging (Albany NY)       Date:  2018-08-29       Impact factor: 5.682

5.  A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.

Authors:  Atsushi Kuno; Yuzuru Ikehara; Yasuhito Tanaka; Kiyoaki Ito; Atsushi Matsuda; Satoru Sekiya; Shuhei Hige; Michiie Sakamoto; Masayoshi Kage; Masashi Mizokami; Hisashi Narimatsu
Journal:  Sci Rep       Date:  2013-01-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.